Top San Diego, CA Biotech Companies (324)
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for pro-innovation/pro-patient policies.
Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery. We pioneer novel deep learning and molecular simulation techniques to accelerate the development of new medicines. Genesis raised its $52M Series A from top tech + biotech investors, Andreessen Horowitz, Rock Springs, and T. Rowe Price. Story: https://techcrunch.com/2020/12/02/genesis-therapeutics-raises-52m-a-round-for-its-ai-focused-drug-discovery-mission/ We deploy our technology to accelerate a pipeline of several internal drug programs. Furthermore, Genesis has announced two significant, multi-target collaborations with Genentech and with Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size. Now we are scaling the team and technology to support many more programs in parallel as well as increasingly difficult protein targets. We currently have a team (genesistherapeutics.ai/company.html#team) of about 35 people, split 50/50 between our ML / software team and our biochem team of veteran drug hunters in our own wetlab space. Our ML + software engineers are top-notch -- many graduates from MIT, UC Berkeley, Stanford. Previously worked at OpenAI, Google, Facebook, MemSQL, Jane Street, Dropbox, etc. We're recruiting pure ML research scientists + software engineers (no bio or chem experience expected) to further our core AI platform as well as scale our drug pipeline. Likewise, we have several openings in chemistry and biology to join our team of biotech + pharma veterans who are deploying the Genesis ML platform to discover novel drug candidates. Please apply on our website, or feel free to reach out via email directly: [email protected]
Maravai brands set the standard in nucleic acid products and services, enzyme development, and biologics safety testing. From producing revolutionary mRNA technologies that drive infectious disease vaccines, cancer vaccines, and other cell and gene therapies to delivering gold-standard bioprocess impurity detection solutions, Maravai is helping life sciences companies overcome their biggest development and manufacturing challenges to streamline and scale from research through clinical trials to commercialization. For over 35 years, Maravai’s brands have served as proven catalysts for innovative, lifesaving technology for humanity. Across our portfolio of brands, we hold numerous patents and offer more than 1,500 innovative products and services, including CleanCap® technology, CleanAmp® hot start PCR, Antibody Affinity Extraction™, EndonucleaseGTP®, PROTEIN A MIX-N-GO™, MockV®, Sterling™, Glen Pak™, Glen Gel-Pak™. Each of our brands are ISO-9001:2015 certified and have earned hundreds of thousands of citations in peer-reviewed scientific publications.
Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our growing menu of diagnostic tests answers important clinical questions to help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment
Epic Sciences develops clinical solutions that accelerate drug development and guided therapy across cancer drug indications. Epic's new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer.
Tr1X Inc. (pr. "Trix") is a biotechnology company dedicated to the development of novel cellular immunotherapies for patients with autoimmune and inflammatory diseases. The Company uses its proprietary platform for the generation of first-in-class cell therapy products aimed at rebalancing the immune system and restoring homeostasis, leading to long term tolerance. Tr1X is headquartered in La Jolla, CA.
We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New Jersey. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.
Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets. We are developing a modular and high-performing DNA sequencing platform that will deliver high-quality data, increase workflow flexibility, and make next-generation sequencing technology more accessible. Our proprietary approach to improving the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation, and biochemistry to drastically decrease run costs and capital costs while delivering high sequencing data quality.
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the company's partners make progress developing and commercializing their products being developed with ENHANZE®. We are a diverse team, who are committed to bringing therapies and results to patients. It's not enough to be qualified and experienced at what you do, we are looking for people who believe in our mission and match our values. We are building a company where people can pursue their career goals in a supportive and collaborative team environment. Visit www.halozyme.com/careers for more details. We are Halozyme.
Our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife Community Guidelines: https://travere.com/community-guidelines/
Altos Labs™ is a biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine. The company comprises a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission. Altos has operations in the San Francisco Bay Area and San Diego, and in Cambridge, UK, with significant collaborations in Japan. Note: Altos Labs will not ask you to download a messaging app for an interview or outlay your own money to get started as an employee. If this sounds like your interaction with people claiming to be with Altos, it is not legitimate and has nothing to do with Altos.
Sequoia Biotech Consulting is a leading life sciences consulting firm that provides a wealth of tenured expertise necessary for quickly and efficiently scaling life science organizations to deliver high-quality therapeutics, diagnostics, and medical devices. The company is headquartered in San Diego, CA, with offices in Boston, MA, and proudly supports a diverse range of life science clients globally. Our team of expert scientists and engineers specializes in optimizing product development, technology transfer, and commercial manufacturing by offering technical guidance, analytical support, and custom solutions for scaling commercial manufacturing operations. Additionally, our team of skilled project managers, business professionals, and quality experts empowers our life science partners to enhance their organizational operations and processes. We provide our clients' teams with the tools, knowledge, and expertise necessary for streamlining processes and leveraging technology for the highest levels of efficiency, quality, and performance. Our goal is to support our clients in developing diagnostics, therapeutics, and medical devices that not only meet but exceed customer expectations, all while maintaining compliance, reducing inefficiencies, minimizing costs, and mitigating risks
ECHO has been built around a singular vision: to rethink traditional microscope design. ECHO has the world's first and only hybrid microscopes that can convert between both upright and inverted configurations. With a portfolio ranging from brightfield, fluorescence, live cell imaging, and confocal, change the way you view science with ECHO's award-winning microscopes. We believe in transparent pricing. Build and Price your own system on our webpage in minutes. Ask about our In person or Virtual Demonstrations
Single cell sequencing solutions company, leveraging patented split-pool barcoding and combinatorial indexing technology, that provides library preparation products that enable unprecedented sample indexing and cell throughput across broad range of genomic, transcriptomic, epigenomic, proteomic and multi-omics applications.
Belharra Therapeutics, Inc. is a privately held drug discovery company whose novel photoaffinity-based chemoproteomics platform is disrupting the drug discovery paradigm. Guided by a diverse team of biotech trailblazers, Belharra’s proprietary noncovalent drug discovery engine is uniquely capable of identifying novel starting points for transformative medicines to address previously impossible-to-treat diseases and conditions. The company’s next generation chemoproteomics platform enables Belharra scientists to identify small molecule drug candidates for any binding site, on any protein, in any conformational state, in any cell type. Originating with Christopher G. Parker, Ph.D. and John Teijaro, Ph.D. at Scripps Research and pioneers in the field of chemical biology and serial biotech founders Benjamin Cravatt, Ph.D. at Scripps Research and Stuart Schreiber, Ph.D. at the Broad Institute of MIT and Harvard, the four co-founded Belharra Therapeutics in 2021 with a $50M Series A financing from Versant Ventures and incubation at Inception Therapeutics. Belharra is headquartered in the San Francisco Bay Area with its primary lab and offices in San Diego, California.
Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its AlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Alluminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug developed on the Alluminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. The company has locations in 5 countries, including the United States, where it is headquartered, Japan, the Netherlands, Taiwan, and Switzerland. For more information, visit www.rakuten-med.com.
Oura is an award-winning and fast-growing startup that helps people track all stages of sleep and activity using the Oura Ring and connected app. By providing daily feedback and practical steps to inspire healthy lifestyles, we've helped hundreds of thousands of people improve their sleep, understand their bodies, and transform their health. We’re on a mission to empower every person to own their inner potential, and we’re seeking talented individuals to join us on our journey. JOIN THE OURA TEAM Oura is full of skilled experts and we’re known to share a good laugh every now and then. We always strive to learn more and dig deeper into our research and analytics, to stay engaged and creative in everything we do. We respect our partners, privacy and the scientific method. We are a multi-disciplinary team of over 100 experts in hardware engineering, software development, machine learning, bioscience, sleep, industrial and UX design, production, marketing and customer experience. Oura Health Ltd.’s HQ and major manufacturing facilities are located in Oulu, Finland. Other locations include Helsinki and San Francisco.
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), with all of its programs currently in the IND-enabling or discovery stage.
Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70% of cervical cancer, 90% of anal cancer and 69% of vulvar cancer. In addition to HPV, Inovio’s optimized plasmid design and delivery technology have been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. Inovio’s most advanced clinical program, VGX-3100, is in Phase 3 development for the treatment of HPV-related cervical pre-cancer. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers, GBM, and prostate cancer, as well as externally funded vaccine development programs in Zika, MERS, Lassa, HIV, and COVID-19. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency, GeneOne Life Science, HIV Vaccines Trial Network, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron, Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. Inovio also is a proud recipient of 2020 Women on Boards “W” designation recognizing companies with more than 20% women on their board of directors.
Work Your Passion. Live Your Purpose.
